Company intelligence / Profile preview

Diadem Biotherapeutics

West Hollywood, California, United Statesdiadembio.com ↗

Ownership: Private
Development stage: Other

Overview

Diadem Biotherapeutics engineers first-in-class extracellular vesicle-based immunotherapies using its proprietary DECOSTAR™ platform. The company focuses on developing safe, powerful, versatile, and economical therapies targeting cancer, chronic inflammatory diseases, and autoimmune conditions. No clinical results have been published yet; the company appears to be in preclinical stages with a broad pipeline under development.

Therapeutic areas: OncologyImmunology
Modalities: Engineered extracellular vesicles (exosomes)Cell-secreted nanovesicles
Industry: Biotech

Drug pipeline

1 asset

Decostar

Preclinical

Partnerships

Awarded Amgen Golden Ticket in August 2021—suggests some level of engagement with Amgen but no formal partnership disclosed.

Beyond the preview

Go deeper on Diadem Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diadem Biotherapeutics.